These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

60 related items for PubMed ID: 16898872

  • 1. Intrinsic cisplatin resistance in lung and ovarian cancer cells propagating in medium acutely depleted of folate.
    Whiteside MA, Piyathilake CJ, Bushell TM, Johanning GL.
    Nutr Cancer; 2006; 54(2):274-84. PubMed ID: 16898872
    [Abstract] [Full Text] [Related]

  • 2. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
    Ibanez de Caceres I, Cortes-Sempere M, Moratilla C, Machado-Pinilla R, Rodriguez-Fanjul V, Manguán-García C, Cejas P, López-Ríos F, Paz-Ares L, de CastroCarpeño J, Nistal M, Belda-Iniesta C, Perona R.
    Oncogene; 2010 Mar 18; 29(11):1681-90. PubMed ID: 20023704
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Study of bcl-2 antisense oligodeoxynucleotides on reversal of cisplatin resistance in ovarian cancer cell line A2780/DDP].
    Li M, Yu LL, Cai LQ, Wang HB, Wang ZH, Wang ZH.
    Zhonghua Fu Chan Ke Za Zhi; 2006 Feb 18; 41(2):121-5. PubMed ID: 16640863
    [Abstract] [Full Text] [Related]

  • 10. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
    Abbosh PH, Montgomery JS, Starkey JA, Novotny M, Zuhowski EG, Egorin MJ, Moseman AP, Golas A, Brannon KM, Balch C, Huang TH, Nephew KP.
    Cancer Res; 2006 Jun 01; 66(11):5582-91. PubMed ID: 16740693
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients.
    Song J, Shih IeM, Salani R, Chan DW, Zhang Z.
    Clin Cancer Res; 2007 Nov 15; 13(22 Pt 1):6842-9. PubMed ID: 17982121
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer].
    Liu GY, Qu QX, Mi RR, Qi J.
    Zhonghua Zhong Liu Za Zhi; 2008 Mar 15; 30(3):184-7. PubMed ID: 18756932
    [Abstract] [Full Text] [Related]

  • 19. Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro.
    Leong CT, Ong CK, Tay SK, Huynh H.
    Oncogene; 2007 Feb 08; 26(6):870-80. PubMed ID: 16862170
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.